Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Bimzelx | bimekizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Bimzelx | bimekizumab | Ankylosing spondylitis | Active | |||
Bimzelx | bimekizumab | Psoriatic arthritis | Active | |||
Blincyto | Blinatumomab | Withdrawn | ||||
Blincyto | Blinatumomab | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia (pediatric) | Reimburse with clinical criteria and/or conditions | Complete | ||
Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Blincyto | Blinatumomab | MRD+ ALL Resubmission | Reimburse with clinical criteria and/or conditions | Complete | ||
Blincyto (Resubmission) | Blinatumomab | Acute Lymphoblastic Leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Bosulif | Bosutinib | Chronic Myeloid Leukemia | Reimburse with clinical criteria and/or conditions | Complete |